RZV Cuts Death but Has No Effect on Heart Health
TOPLINE: Recombinant zoster vaccine (RZV) had no significant effect on major adverse cardiovascular events; however, it reduced all-cause mortality in patients with immune-mediated inflammatory diseases receiving Janus kinase inhibitors. The mortality benefit was particularly notable in women and patients aged 65 years or older. METHODOLOGY: Researchers conducted a new user design study utilizing the TriNetX … Read more